Leber's Hereditary Optic Neuropathy | A Drug Pipeline Analysis Report 2018 | Technavio

Technavio has published a new report on the drug development pipeline for Leber’s hereditary optic neuropathy, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

LONDON--()--Technavio has announced their latest drug pipeline analysis report on Leber’s hereditary optic neuropathy. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat Leber’s hereditary optic neuropathy.

This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Leber’s hereditary optic neuropathy: Market overview

Leber’s hereditary optic neuropathy (LHON) is the most common mitochondrially inherited disease, which is associated with mitochondrial base pair mutations. The base pairs of mitochondria, which get affected due to LHON are G11778A (guanine to adenine at position 1778), T14484C (tyrosine to cytosine at position 14484), and G3460A (guanine to adenine at position 3460). The occurrence of mutations in these pairs affects respiratory chain complex I genes, mitochondrial genes ND1, ND4, and ND6, and others. In individuals suffering from this disease, the vision gets impacted due to degeneration of retinal ganglion cells and their axons, which leads to an acute or subacute loss of central vision of both eyes. The disease mainly impacts the central vision, thus causing a problem in reading, writing, and recognizing whereas peripheral vision remains unimpacted.

According to a senior market research analyst at Technavio, “LHON is one of the most common optic neuropathies found in young adult males. According to the US National Library of Medicines, the prevalence of LHON in most populations is unknown. It affects 1 in 30,000-50,000 people in Northeast England and Finland.”

Leber’s hereditary optic neuropathy: Segmentation analysis

This pipeline analysis report segments the Leber's hereditary optic neuropathy market based on therapies employed (monotherapy), RoA (ophthalmic, intravenous, intravitreal, and oral), therapeutic modality (small molecule, gene therapy, and peptide), targets (cardiolipin, NADH dehydrogenase subunit 4, and peroxiredoxin enzyme), geographical segmentation (US, UK, France, and Italy) and recruitment status (active, not recruiting, completed, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Based on therapeutic modality, around 60% of the molecules that are being investigated for the treatment of Leber's hereditary optic neuropathy are small molecule.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Release Summary

Technavio has published a new report on the drug development pipeline for Leber’s hereditary optic neuropathy (LHON).


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200